BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

Stock Information for BioLineRx Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioLineRx Ltd.

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx to Report First Quarter 2026 Results on May 27, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.